| 1 |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| 2 |
Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J (Engl), 2022, 135(5): 584-590.
|
| 3 |
Yoshida N, Doyama H, Yano T, et al. Early gastric cancer detection in high-risk patients: a multicentre randomised controlled trial on the effect of second-generation narrow band imaging[J]. Gut, 2021, 70(1): 67-75.
|
| 4 |
Eusebi LH, Telese A, Marasco G, et al. Gastric cancer prevention strategies: A global perspective[J]. J Gastroenterol Hepatol, 2020, 35(9): 1495-1502.
|
| 5 |
Wei C, Du X, Hu J, et al. Perioperative chemotherapy versus adjuvant chemotherapy in patients with resectable gastric cancer: A systematic review with meta-analysis[J]. Crit Rev Oncol Hematol, 2023, 31: 104082.
|
| 6 |
Xiao T, Xiao Y, Wang W, et al. Targeting EphA2 in cancer[J]. J Hematol Oncol, 2020, 13(1): 114.
|
| 7 |
Tomiyama E, Fujita K, Matsuzaki, et al. EphA2 on urinary extracellular vesicles as a novel biomarker for bladder cancer diagnosis and its effect on the invasiveness of bladder cancer [J]. Br J Cancer, 2022, 127, 1312-1323.
|
| 8 |
Kim J, Chang IY, You HJ. Interactions between EGFR and EphA2 promote tumorigenesis through the action of Ephexin1[J]. Cell Death Dis, 2022, 13(6): 528.
|
| 9 |
Harris ED, Sharpe JC, Strozen T, et al. The EphA2 receptor regulates invasiveness and drug sensitivity in canine and human osteosarcoma cells[J]. Cells, 2024, 13(14): 1201.
|
| 10 |
Zhou Y, Sakurai H. Emerging and diverse functions of the EphA2 noncanonical pathway in cancer progression[J]. Biol Pharm Bull, 2017, 40(10): 1616-1624.
|
| 11 |
Li Y, Hu Y, Zhan X, et al. Meta-analysis reveals Helicobacter pylori mutual exclusivity and reproducible gastric microbiome alterations during gastric carcinoma progression[J]. Gut Microbes, 2023, 15(1): 2197835.
|
| 12 |
Leite M, Marques MS, Melo J, et al. Helicobacter Pylori targets the EPHA2 Receptor tyrosine kinase in gastric cells modulating key cellular functions[J]. Cells, 2020, 9(2): 513.
|
| 13 |
Hirabayashi M, Georges D, Clifford GM, et al. Estimating the global burden of epstein-barr virus-associated gastric cancer: A systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2023, 21(4): 922-930.e21.
|
| 14 |
Fekadu S, Kanehiro Y, Kartika AV, et al. Gastric epithelial attachment of helicobacter pylori induces EphA2 and NMHC-IIA receptors for epstein-barr virus[J]. Cancer Sci, 2021, 112(11): 4799-4811.
|
| 15 |
Shi D, Liu W, Zhang X, et al. MiR-BART1-3p and BART18-5p inhibit cell migration, proliferation and activate autophagy in Epstein-Barr virus-associated gastric cancer by targeting erythropoietin-producing human hepatocellular 2[J]. Virus Genes, 2023, 59(5): 703-715.
|
| 16 |
Ren HY, Shen JX, Mao XM, et al. Correlation between tumor vasculogenic mimicry and poor prognosis of human digestive cancer patients: A systematic review and meta-analysis[J]. Pathol Oncol Res, 2019, 25(3): 849-858.
|
| 17 |
Kim HS, Won YJ, Shim JH, et al. Role of EphA2-PI3K signaling in vasculogenic mimicry induced by cancer-associated fibroblasts in gastric cancer cells[J]. Oncol Lett, 2019, 18(3): 3031-3038.
|
| 18 |
Kim HS, Won YJ, Shim JH, et al. Morphological characteristics of vasculogenic mimicry and its correlation with EphA2 expression in gastric adenocarcinoma[J]. Sci Rep, 2019, 9(1): 3414.
|
| 19 |
Hong HN, Won YJ, Shim JH, et al. Cancer-associated fibroblasts promote gastric tumorigenesis through EphA2 activation in a ligand-independent manner[J]. J Cancer Res Clin Oncol, 2018, 144(9): 1649-1663.
|
| 20 |
Zhou Y, Oki R, Tanaka A, et al. Cellular stress induces non-canonical activation of the receptor tyrosine kinase EphA2 through the p38-MK2-RSK signaling pathway[J]. J Biol Chem, 2023, 299(5): 104699.
|
| 21 |
Han J, Wang L, Lv H, et al. EphA2 inhibits SRA01/04 cells apoptosis by suppressing autophagy via activating PI3K/Akt/mTOR pathway[J]. Arch Biochem Biophys, 2021, 711: 109024.
|
| 22 |
Mao L, Yuan W, Cai K, et al. EphA2-YES1-ANXA2 pathway promotes gastric cancer progression and metastasis[J]. Oncogene, 2021, 40(20): 3610-3623.
|
| 23 |
Peng Q, Chen L, Wu W, et al. EPH receptor A2 governs a feedback loop that activates Wnt/β-catenin signaling in gastric cancer[J]. Cell Death Dis, 2018, 9(12): 1146.
|
| 24 |
Huang C, Yuan W, Lai C, et al. EphA2-to-YAP pathway drives gastric cancer growth and therapy resistance[J]. Int J Cancer, 2020, 146(7): 1937-1949.
|
| 25 |
Wang F, Zhang H, Cheng Z. EPHA2 promotes the invasion and migration of human tongue squamous cell carcinoma Cal-27 cells by enhancing AKT/mTOR signaling pathway[J]. Biomed Res Int, 2021, 2021: 4219690.
|
| 26 |
Wang DH, Zhang YJ, Zhang SB, et al. Geldanamycin mediates the apoptosis of gastric carcinoma cells through inhibition of EphA2 protein expression[J]. Oncol Rep, 2014, 32(6): 2429-2436.
|
| 27 |
Lee H, Lee J, Sohn I, et al. To excavate biomarkers predictive of the response for capecitabine plus RAD001 through nanostring-based multigene assay in advanced gastric cancer patients[J]. J Cancer, 2016, 7(15): 2173-2178.
|
| 28 |
Wen Q, Chen Z, Chen Z, et al. EphA2 affects the sensitivity of oxaliplatin by inducing EMT in oxaliplatin-resistant gastric cancer cells[J]. Oncotarget, 2017, 8(29): 47998-48011.
|
| 29 |
Chen Z, Liu Z, Gao J, et al. EPHA2/MAPK pathway confers acquired resistance of afatinib in gastric cancer ANN ONCOL[J]. ANN ONCOL, 2018, 29.
|
| 30 |
Lee PC, Chen ST, Kuo TC, et al. C1GALT1 is associated with poor survival and promotes soluble Ephrin A1-mediated cell migration through activation of EPHA2 in gastric cancer[J]. Oncogene, 2020, 39(13): 2724-2740.
|
| 31 |
Huang J, He Y, Mcleod HL, et al. miR-302b inhibits tumorigenesis by targeting EphA2 via Wnt/ β-catenin/EMT signaling cascade in gastric cancer[J]. BMC Cancer, 2017, 17(1): 886.
|
| 32 |
Song B, Lin HX, Dong LL, et al. MicroRNA-338 inhibits proliferation, migration, and invasion of gastric cancer cells by the Wnt/β-catenin signaling pathway[J]. Eur Rev Med Pharmacol Sci, 2018, 22(5): 1290-1296.
|
| 33 |
Li R, Hu Z, Wang Z, et al. miR-125a-5p promotes gastric cancer growth and invasion by regulating the Hippo pathway[J]. J Clin Lab Anal, 2021, 35(12): e24078.
|